NCT00257348

Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer

A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: University of California, Irvine · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the effectiveness and side effects of the drugs capecitabine and docetaxel in the treatment of cervical cancer. Capecitabine is approved by the FDA for the treatment of breast and colon cancer. Docetaxel is approved in the treatment of breast and lung cancer. The use of capecitabine and docetaxel in this study for the treatment of cervical cancer is considered investigational. Eligible subjects will take the drug capecitabine (Xeloda) by mouth twice a day every 12 hours, for fourteen consecutive days followed by a 7 day rest period. Subjects will also receive the drug docetaxel (Taxotere) intravenously (in the vein) every three weeks.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine
DRUG	Docetaxel

Timeline

• Start date: 2004-03-01
• Primary completion: 2007-07-01
• Completion: 2007-07-01
• First posted: 2005-11-22
• Last updated: 2013-02-08

Locations

1 site across 1 country: United States